At Pacifichem 2010 in Honolulu ?forzest.

Amira’s clinical-stage DP2 receptor antagonist program data to be presented at Pacifichem 2010 Amira Pharmaceuticals, Inc. Announced today that it’ll present preclinical and scientific data from its DP2 receptor antagonist system on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii ?forzest .D., in a demonstration titled ‘Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse types of COPD and asthma.’ ‘We have become excited about the two structurally distinct scientific stage molecules, AM211 and AM461,’ said Peppi Prasit, Ph.D., Chief Scientific Officer.’ The DP2 receptor can be area of the Arachidonic Acid pathway and is normally also referred to as CRTH2, or chemoattractant receptor-homologous molecule expressed in Th2 lymphocytes.

Amneal delivers superior program levels, quality products, and dynamic value throughout the pharmaceutical industry.. Amneal Pharmaceuticals to acquire assets of Interpharm Holdings Amneal Pharmaceuticals, LLC has declared the execution of an Asset Purchase Agreement for Amneal’s wholly-owned subsidiary, Amneal Pharmaceuticals of New York, LLC, to acquire the assets, business and facilities of Interpharm. The acquisition includes Interpharm’s services on Long Island, New York as well as the intellectual house including ANDA’s, processes and technology.